Bill Taranto

speaker

527 appearances 1 recordings 1 series first heard Jan 2026 last heard 8 Jan

Bill Taranto’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 1 in all, peaking in Jan 2026 with 1.

Appearances

newest first · ▶ plays the moment

Vanguards of Healthcare by Bloomberg Intelligence · Merck’s GHI Fund and the Push to Rewire Pharma's Future · 8 Jan 2026 podcast

It's not just the doctor prescribing you, but the doctor looks at it, it gets adjudicated at typically a third party or

You know, and it could be rejected.

There's formulary.

You know, there's all these different entities that touch your prescription before you actually end up at the pharmacy.

And most people don't understand it.

And following how the money flows is really important.

So we call it connecting the dots.

And I think one of the things our team does really well is they understand how to connect the dots about all the different pieces of the industry and how it actually works.

And I think finally, you know, we're really good investors.

because we understand all those things.

If you look at the history of the fund, it's been really successful.

You know, we've done 70 plus close to 80 investments, you know, and over the time we've actually only had six complete, you know, losses and we've accessed 40 some odd companies and, you know, we're sitting on another 40 some odd companies.

So you can see that

We're actually not that one in 10 investor.

We actually have a really good history and track record of making good investments.

And as I said earlier, the fact that we now have a lot of commercial agreements, we've shown that we also could be very strategic, not only the Merck, but the industry.

So there's a lot of different things that differentiate us as we think about how we are, you know, sort of, you know, different than an independent.

I think the last thing too that I'll say is, you know, we don't struggle with fundraising, right?

You know, we have a single LP that is Merck and we're a $600 million evergreen access, believe it or not, to another $150 million should we need it.

And one of the things that we never struggle with is trying to have to fundraise all the time.

Showing 201–220 of 527 · page 11 of 27